Inaktiver Wert

Andere Sprachen Mylan Inc Nasdaq

Aktien

US6285301072

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

17.04.	Idorsia bleibt weiter in einer finanziell schwierigen Lage	AW
17.04.	Idorsia sucht weiter nach Lösung für finanziellen Engpass	AW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Viatris to Participate in the BofA Securities 2024 Health Care Conference	02.05.
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health	01.05.
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	18.04.
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	18.04.
Idorsia poursuit les discussions avec ses créanciers	17.04.
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024	16.04.
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	15.04.
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15.04.
Viatris Appoints Corinne Le Goff as Chief Commercial Officer	15.04.
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	15.04.
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada	15.04.
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	15.04.
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	15.04.
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	11.04.
UK's Theramex sees no impact to HRT products supply after CMA probe	05.04.
Pharma deal could reduce choice and lead to higher prices for HRT treatments	04.04.
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	04.04.
UK watchdog says Theramex-Viatris deal raises competition concerns	04.04.
Viatris Announces the Launch of RYZUMVl 0.75% in the United States	02.04.
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	01.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mylan Inc Nasdaq

Aktien

US6285301072

Andere Sprachen

Filter